Such structural and functional versatility translates into therapeutic potential, as BTLA blockade could complement existing checkpoint inhibitors and restore anti-tumor immunity in cancers resistant to PD-1 or CTLA-4 targeting therapies. The gene discussed is CTLA4; the disease is neoplasm.